Europe sees record STI surge
Analysis based on 25 articles · First reported May 21, 2026 · Last updated Jun 02, 2026
The surge in STIs across Europe could increase demand for diagnostic tests, antibiotics, and vaccines, potentially benefiting pharmaceutical and healthcare companies. However, it also highlights systemic weaknesses in public health infrastructure, which could lead to increased healthcare costs and reduced productivity in the long term. The development and rollout of new vaccines, such as the gonorrhoea vaccine in the United Kingdom, could present investment opportunities in the biotech sector.
Europe is experiencing a significant public health crisis with bacterial sexually transmitted infections (STIs) reaching record highs in 2024, according to the European Union — European Centre for Disease Prevention and Control (ECDC). Gonorrhoea cases surged by 303% since 2015 to 106,331, and syphilis cases more than doubled to 45,577. Congenital syphilis cases nearly doubled from 2023 to 2024, indicating serious gaps in prevention and care during pregnancy. Spain reported the highest number of cases among participating countries. The ECDC attributes this rise to widening gaps in testing and prevention, outdated national strategies, and uneven healthcare services. Bruno Ciancio, from the ECDC, emphasized the severe complications of untreated STIs. The World Health Organization Europe has set a 2030 target for congenital syphilis elimination. Countries like the United Kingdom have rolled out gonorrhoea vaccines, but the ECDC recommends strengthening screening, improving access to treatment, and enhancing partner notification systems across Europe.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard